The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The study, presented by Guillermo Garcia-Manero, MD, interim chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, evaluated the efficacy and safety of venetoclax in combination with azacitidine in treatment-naive patients with high-risk MDS.
In this Meet the Professor session in acute myeloid leukemia, Jeffrey Lancet, MD, chair of the Department of Malignant Hematology at the Moffitt Cancer Center in Tampa, Florida, presents on the future role of CPX-351 The session was presented at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025).
Hagop Kantarjian, MD, interviews Nicholas Short, MD, on treatment sequencing in precursor B-cell ALL and in the relapsed or refractory setting.
In this interview from the Thirteenth annual meeting of the Society of Hematologic Oncology (SOHO 2025), Hagop Kantarjian, MD, hosts Nicholas Short, MD, both from the University of Texas MD Anderson Cancer Center, to discuss progress in acute lymphoblastic leukemia (ALL) treatment.
In this video interview, Hagop Kantarjian, MD, speaks with Michael Mauro, MD, leader of the CML program at Memorial Sloan Kettering Cancer Center, on Dr. Mauro’s SOHO 2025 abstract on […]
Attendees of SOHO 2025 will get a closer look at positive early safety and efficacy data for the novel Bruton’s tyrosine kinase (BTK)-targeted drug bexobrutideg in heavily pretreated Waldenström macroglobulinemia (WM).
Updated results from an early-phase chronic lymphocytic leukemia trial of heavily pretreated patients showed that once-daily dosing of the Bruton’s tyrosine kinase (BTK) inhibitor bexobrutideg was well-tolerated.
The trial, which investigated the efficacy and safety of frontline subcutaneous mosunetuzumab, a CD20/CD30-directed bispecific antibody, was part of the MorningSun basket trial. In MZL, chemoimmunotherapy remains standard of care, but investigators are hoping to move to chemo-free regimens with novel therapies.
With more than 10,500 global members, SOHO is poised to educate hematologic oncologists from every corridor of the Earth.
Death from chronic lymphocytic leukemia (CLL) in the U.S. has been declining, but disparities in outcomes persist, according to a population study of data from 1999-2020.
